Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 16;25(18):4240.
doi: 10.3390/molecules25184240.

Elaeagnus angustifolia Plant Extract Inhibits Epithelial-Mesenchymal Transition and Induces Apoptosis via HER2 Inactivation and JNK Pathway in HER2-Positive Breast Cancer Cells

Affiliations

Elaeagnus angustifolia Plant Extract Inhibits Epithelial-Mesenchymal Transition and Induces Apoptosis via HER2 Inactivation and JNK Pathway in HER2-Positive Breast Cancer Cells

Ayesha Jabeen et al. Molecules. .

Abstract

Elaeagnus angustifolia (EA) is a medicinal plant used for treating several human diseases in the Middle East. Meanwhile, the outcome of EA extract on HER2-positive breast cancer remains nascent. Thus, we herein investigated the effects of the aqueous EA extract obtained from the flowers of EA on two HER2-positive breast cancer cell lines, SKBR3 and ZR75-1. Our data revealed that EA extract inhibits cell proliferation and deregulates cell-cycle progression of these two cancer cell lines. EA extract also prevents the progression of epithelial-mesenchymal transition (EMT), an important event for cancer invasion and metastasis; this is accompanied by upregulations of E-cadherin and β-catenin, in addition to downregulations of vimentin and fascin, which are major markers of EMT. Thus, EA extract causes a drastic decrease in cell invasion ability of SKBR3 and ZR75-1 cancer cells. Additionally, we found that EA extract inhibits colony formation of both cell lines in comparison with their matched control. The molecular pathway analysis of HER2 and JNK1/2/3 of EA extract exposed cells revealed that it can block HER2 and JNK1/2/3 activities, which could be the major molecular pathway behind these events. Our findings implicate that EA extract may possess chemo-preventive effects against HER2-positive breast cancer via HER2 inactivation and specifically JNK1/2/3 signaling pathways.

Keywords: EMT; Elaeagnus angustifolia; apoptosis; breast cancer; chemoprevention.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
(a,b) The effects of different concentrations of Elaeagnus angustifolia (EA) plant extract on cell proliferation of HER2-positive breast cancer cell lines SKBR3 (a) and ZR75-1 (b) at 48 h. Data indicate an inverse relation between concentrations of EA extract and cell proliferation in both SKBR3 and ZR75-1 cell lines. Data are expressed as percent of growth ± SEM.
Figure 2
Figure 2
(a,b) Flow cytometry data analysis of SKBR3 and ZR75 cells after EA-treatment. Data demonstrate an increase in G0/G1 phase with simultaneous reduction in S and G2/M phases in both cell lines. Meanwhile, there is a significant increase in cell apoptosis (Sub/G1 phase) of SKBR3 cells treated with EA, and a small increase in cell apoptosis of treated ZR75 cells.
Figure 3
Figure 3
(a,b) Induction of apoptosis by EA extract in SKBR3 (a, b) and ZR75 (c, d) cells, as determined by Annexin V-FITC and 7-AAD apoptosis assay.
Figure 4
Figure 4
(a,b) EA plant extract induces morphological changes in HER2-positive cell lines, SKBR3 and ZR75-1. (a) We observe that treatment for 48 h with 100 and 200 μL/mL of EA extract induces epithelial transition and the formation of a monolayer of cells in both cell lines, in comparison with untreated (control) cells which display a round phenotype and form multilayers; arrows indicate epithelial morphology with clear cell-cell adhesion. (b) At three days of treatment of SKBR3, ZR75-1, and HNME-E6/E7 cell lines with 200 μL/mL of EA plant extract, the two cancer cell lines start detaching from the surface of the tissue culture dish, indicating cell death; this observation was not noted in the HNME-E6/E7 cells (images a and b at ×20 magnification).
Figure 5
Figure 5
(a,b): The effects of EA flower extract on cell invasion of human HER2-positive breast cancer cells. EA extract inhibits cell invasion ability of SKBR3 (a) and ZR75-1 (b) cell lines by approximately 70% in comparison with their matched control cells (unexposed) (p < 0.05). Boyden chambers were used to assess cell-invasion ability of SKBR3 and ZR75-1 cell lines. Cancer cells treated for 24 h with 100 and 200 µL/mL EA plant extract showed a significant inhibition of cell invasion in both cell lines, when compared with their matched control (p < 0.05). Data are quantified by normalizing the number of invasive cells by their total number.
Figure 6
Figure 6
(a,b) Effect of EA flower extract on colony formation, in soft agar, in human HER2-positive cancer cell lines, SKBR3 (a) and ZR75-1 (b). EA extract inhibits colony formation of SKBR3 and ZR75-1, in comparison with their matched control cells (images of figure a,b at ×10 magnification). Colony formation in soft agar is a solid indicator of tumor formation in vivo. The colonies were counted manually and expressed as percentage of treatment relative to the control (mean ± SEM).
Figure 7
Figure 7
(a,b) Protein expression and molecular mechanisms of EA inhibitory actions in SKBR3 cell line. This plant extract induces an overexpression of E-cadherin, β-catenin, and downregulation of vimentin and fascin, while upregulating pro-apoptotic markers (Bax and Caspase-3), in comparison with their control and inhibiting anti-apoptotic markers (Bcl-2). Furthermore, EA plant extract inhibits the phosphorylation of ErbB2 and β-catenin, as well as the expression of JNK1/2/3. β-actin was used as a control for the proteins amount in this assay. Cells were treated with 100 and 200 μL/mL of EA extract for 48 h, as explained in the materials and methods and the results sections. (a) Blot image and (b) quantification of bands.
Figure 8
Figure 8
(a,b) Protein expression and molecular mechanisms of EA inhibitory actions in ZR75 cell line. This plant extract induces an overexpression of E-cadherin, β-catenin, and downregulation of vimentin and fascin; in addition, pro-apoptotic markers Bax and Caspase-3 are upregulated in comparison with their control, while anti-apoptotic marker Bcl-2 is inhibited. Furthermore, EA plant extract inhibits the phosphorylation of ErbB2 and β-catenin, as well as JNK1/2/3 expression. β-actin served as a control in this assay. Cells were treated with 100 and 200 μL/mL of EA extract for 48 h, as explained in the materials and Methods section. (a) Blot image and (b) quantification of bands.

Similar articles

Cited by

References

    1. Ferlay J., Colombet M., Soerjomataram I., Mathers C., Parkin D.M., Piñeros M., Znaor A., Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer. 2019;144:1941–1953. doi: 10.1002/ijc.31937. - DOI - PubMed
    1. Gupta I., Burney I., Al-Moundhri M.S., Tamimi Y. Molecular genetics complexity impeding research progress in breast and ovarian cancers. Mol. Clin. Oncol. 2017;7:3–14. doi: 10.3892/mco.2017.1275. - DOI - PMC - PubMed
    1. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752. doi: 10.1038/35021093. - DOI - PubMed
    1. Sareyeldin R.M., Gupta I., Al-Hashimi I., Al-Thawadi H.A., Al Farsi H.F., Vranic S., Al Moustafa A.-E. Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer. Cancers. 2019;11:646. doi: 10.3390/cancers11050646. - DOI - PMC - PubMed
    1. Giordano S.H., Temin S., Chandarlapaty S., Crews J.R., Esteva F.J., Kirshner J.J., Krop I.E., Levinson J., Lin N.U., Modi S., et al. Systemic Therapy for Patients with Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Clinical Practice Guideline Update. J. Clin. Oncol. 2018;36:2736–2740. doi: 10.1200/JCO.2018.79.2697. - DOI - PubMed

MeSH terms